Bioequivalence of two omega-3 fatty acid ethyl ester formulations: A case of clinical pharmacology of dietary supplements

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 60-65

  Galli, Claudio ^a   Maggi, Franco M ^a   Risé, Patrizia ^a   Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bioequivalence; Clinical; Omega 3 fatty acids; Pharmacokinetics; Pharmacology

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; HUMANS; MALE; THERAPEUTIC EQUIVALENCY;

EID: 84862152491     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04174.x     Document Type: Article

References (29)

1. Gurley BJ. Clinical pharmacology of dietary supplements: an evolving relationship. Clin Pharmacol Ther 2010; 87: 235-8.
2. Haller CA. Nutraceuticals: has there been any progress? Clin Pharmacol Ther 2010; 87: 137-41.
3. Tsourounis C, Bent S. Why change is needed in research examining dietary supplements. Clin Pharmacol Ther 2010; 87: 147-9.
4. American Dietetic Association. Position of the American Dietetic Association: nutrient supplementation. J Am Diet Assoc 2009; 109: 2073-85.
5. Eslick GD, Howe PRC, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009; 136: 4-16.
6. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular diseases: 2006 update: endorsed by National Heart, Lung and Blood Institute. Circulation 2006; 113: 2363-72.
7. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk marker in patients with type 2 diabetes. Diabetologia 2007; 50: 1593-602.
8. Yashodhara BM, Umakanth S, Pappachan JM, Bhat SK, Kamath R, Choo BH. Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgrad Med J 2009; 85: 84-90.
9. Galli C, Risé PT, Sirtori CR. Fish, long-chain omega-3 polyunsaturated fatty acids and cardiovascular disease. Hot Topics in Cardiology 2008; 11: 7-22.
10. Holub BJ. Docosohexaenoic acid (DHA) and cardiovascular risk factors. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 199-204.
11. Musa-Veloso K, Binns MA, Kocenas AC, Poon T, Elliot JA, Rice H, Hoppedal-Olsen H, Lloyd H, Lemke S. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 2010; 68: 155-67.
12. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 2007; 27: 715-28.
13. Hibbeln JR, Nieminen LRG, Blasbalg TL, Riggs JA, Lands WEM. Healthy intakes of n-3 and n-6 fatty acids : estimations considering worldwide diversity. Am J Clin Nutr 2006; 83 (Suppl.): 1483S-1493S.
14. Committee for Medicinal Products for Human use (CHMP). EMEA Guideline on the investigation of bioequivalence. London 20 January 2010. Doc Ref. CPMP/EWP/QWP/1401/98 Rev. 1/Corr**.
15. Nordoy A, Barstad L, Connor WE, Hatcher L. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991; 53: 1185-90.
16. Rusca A, Di Stefano AFD, Doig MV, Scarsi C, Perucca E. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 503-10.
17. Marangoni F, Colombo C, Galli C. A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans : applicability to nutritional and epidemiological studies. Anal Biochem 2004; 326: 267-72.
18. Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc 2009; 109: 1076-81.
19. Giltay EJ, Gooren LJG, Toorians AWFT, Katan MB, Zock PL. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am J Clin Nutr 2004; 80: 1167-74.
20. Galli C, Risé P, Grezzi S, Marangoni F. Fast determination of fatty acids in whole blood collected from fingertips: application to the assessment of fatty acid patterns (and various indexes) in population studies. In: A balanced Omega 6/Omega 3 Fatty Acid Ratio, Cholesterol and Coronary Heart Disease (World Review Nutr Diet 2009), eds Simopoulos AP, De Meeter F. Basel: Karger, 2009; 100: 35-45.
21. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010; 303: 250-7.
22. Visioli F, Risé P, Barassi MC, Marangoni F, Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 2003; 38: 415-8.
23. Germino FW, Neutel J, Nonaka M, Hendler SS. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J Clin Hypertens 2010; 12: 153-9.
24. Fukuda DH, Smith AE, Kendall KL, Dwyer TR, Kerksick CM, Beck TW, Cramer JT, Stout JR. The effects of creatine loading and gender on anaerobic running capacity. J Strength Cond Res 2010; 24: 1826-33.
25. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91.
26. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, Birreci A, Koverech A. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000; 10: 247-51.
27. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197: 12-24.
28. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, for JELIS Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomized open-lable, blinded endpoint analysis. Lancet 2007; 369: 1090-8.
29. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y, for JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercolesterolemia. Circ J 2010; 74: 510-7.